A Dec. 27 decision by the U.S. appeals court paused the U.S. International Trade Commission’s ban on the Apple Watch Series 9 and Ultra 2 models, which allegedly violated a patent held by medical technology company Masimo. Masimo claims the watch’s blood oxygen feature was copied from their technology.
In 2013, Apple considered acquiring Masimo, but decided instead to hire engineers to build the technology internally, according to the report. Other companies allege Apple similarly began partnership or acquisition talks but abandoned them after the smaller companies shared details about their technology. Apple has redesigned elements of the watch and is also asking for the U.S. Customs and Border Protection for approval to import the devices.
Apple says it did not copy the smartwatch, or any other, design for its products.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
